Description of a New Predictive Modeling Approach That Correlates the Risk and Associated Cost of Well-Defined Diabetes-Related Complications With Changes in Glycated Hemoglobin (HbA1c)
- PMID: 27510441
- PMCID: PMC5478016
- DOI: 10.1177/1932296816662048
Description of a New Predictive Modeling Approach That Correlates the Risk and Associated Cost of Well-Defined Diabetes-Related Complications With Changes in Glycated Hemoglobin (HbA1c)
Abstract
The modeling approach described here is designed to support the development of spreadsheet-based simple predictive models. It is based on 3 pillars: association of the complications with HbA1c changes, incidence of the complications, and average cost per event of the complication. For each pillar, the goal of the analysis was (1) to find results for a large diversity of populations with a focus on countries/regions, diabetes type, age, diabetes duration, baseline HbA1c value, and gender; (2) to assess the range of incidences and associations previously reported. Unlike simple predictive models, which mostly are based on only 1 source of information for each of the pillars, we conducted a comprehensive, systematic literature review. Each source found was thoroughly reviewed and only sources meeting quality expectations were considered. The approach allows avoidance of unintended use of extreme data. The user can utilize (1) one of the found sources, (2) the found range as validation for the found figures, or (3) the average of all found publications for an expedited estimate. The modeling approach is intended for use in average insulin-treated diabetes populations in which the baseline HbA1c values are within an average range (6.5% to 11.5%); it is not intended for use in individuals or unique diabetes populations (eg, gestational diabetes). Because the modeling approach only considers diabetes-related complications that are positively associated with HbA1c decreases, the costs of negatively associated complications (eg, severe hypoglycemic events) must be calculated separately.
Keywords: HbA1c; approach; complications; cost; diabetes; model.
Conflict of interest statement
Figures



Similar articles
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.Health Technol Assess. 2004 Nov;8(45):iii, 1-57. doi: 10.3310/hta8450. Health Technol Assess. 2004. PMID: 15525480
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
Cited by
-
Modeling of Diabetes and Its Clinical Impact.J Diabetes Sci Technol. 2018 Sep;12(5):976-984. doi: 10.1177/1932296818785642. Epub 2018 Jul 13. J Diabetes Sci Technol. 2018. PMID: 30003801 Free PMC article. Review.
-
Prediction of pharmaceutical and non-pharmaceutical expenditures associated with Diabetes Mellitus type II based on clinical risk.PLoS One. 2024 Jun 4;19(6):e0301860. doi: 10.1371/journal.pone.0301860. eCollection 2024. PLoS One. 2024. PMID: 38833461 Free PMC article.
-
Randomised controlled trials on prevention, diagnosis and treatment of diabetes in African countries: a systematic review.BMJ Open. 2022 May 11;12(5):e050021. doi: 10.1136/bmjopen-2021-050021. BMJ Open. 2022. PMID: 35545395 Free PMC article.
-
The potential role of angiopoietin-like protein-8 in type 2 diabetes mellitus: a possibility for predictive diagnosis and targeted preventive measures?EPMA J. 2019 Aug 6;10(3):239-248. doi: 10.1007/s13167-019-00180-3. eCollection 2019 Sep. EPMA J. 2019. PMID: 31462941 Free PMC article.
-
Improving Access to the Glycated Hemoglobin Test in Rural Communities With Point-of-Care Devices: An Application Study.Front Med (Lausanne). 2021 Nov 22;8:734306. doi: 10.3389/fmed.2021.734306. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34881257 Free PMC article.
References
-
- Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997;20:735-744. - PubMed
-
- Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care. 1997;20:725-734. - PubMed
-
- Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283:889-896. - PubMed
-
- Brown JB, Russell A, Chan W, Pedula K, Aickin M. The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract. 2000;50(suppl 3):S15-S46. - PubMed
-
- Eddy DM, Schlessinger L. Validation of the Archimedes diabetes model. Diabetes Care. 2003;26:3102-3110. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical